SUPN inks deal to acquire Sage Therapeutics for up to $795 million, securing rights to depression drug Zurzuvae.

Sage Therapeutics (SAGE) witnessed a jump in share price last session on above-average trading volume. The latest trend in ...

Sage Therapeutics shares gained 0.4% to trade at $9.11 on Tuesday. These analysts made changes to their price targets on Sage ...

Eli Lilly has confirmed plans for a $1.3 billion takeover bid for Verve Therapeutics, upgrading a collaboration between the ...

Recent health headlines spotlight Surgery Partners rejecting Bain Capital's offer, the U.S. betting on China's drug potential ...

Calm returned to Wall Street on Monday, and U.S. stocks rose, while oil prices gave back some of their initial spurts ...

Calm returned to Wall Street on Monday, and U.S. stocks rose, while oil prices gave back some of their initial spurts following Israel’s attack on Iranian nuclear and military targets at the end of ...

Calm returned to Wall Street, and U.S. stocks rallied, while oil prices gave back some of their initial spurts following ...

Calm returned to Wall Street on Monday, and U.S. stocks rose, while oil prices gave back some of their initial spurts following Israel’s attack on Iranian nuclear and military targets at the end of ...

As of June 17, 2025, three stocks in the health care sector could be flashing a real warning to investors who value momentum ...

Big Pharma executives have not been shy about their desire for deals, but companies have been battling macro headwinds ...

Calm was returning to Wall Street, and U.S. stocks were rallying on Monday, while oil prices were giving back some of their ...